It has been found that the membrane permeability of peptide compounds can be improved by making at least one of amino acids constituting the peptide compound be an amino acid having a side chain capable of forming an intramolecular hydrogen bond.

It has been found that the membrane permeability of peptide compounds can be improved by making at least one of amino acids constituting the peptide compound be an amino acid having a side chain capable of forming an intramolecular hydrogen bond.

The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X.sup.1 represents an oxygen atom or the like; X.sup.2 represents an oxygen atom; X.sup.3 represents —NH—; X.sup.4 represents a hydrogen atom or the like; R.sup.1 represents —C(R.sup.11)(R.sup.12)— or the like; R.sup.11 and R.sup.12 are the same or different and each represents a hydrogen atom or the like; R.sup.2 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.3 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.4 represents a hydrogen atom or the like] or a salt thereof.

The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X.sup.1 represents an oxygen atom or the like; X.sup.2 represents an oxygen atom; X.sup.3 represents —NH—; X.sup.4 represents a hydrogen atom or the like; R.sup.1 represents —C(R.sup.11)(R.sup.12)— or the like; R.sup.11 and R.sup.12 are the same or different and each represents a hydrogen atom or the like; R.sup.2 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.3 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.4 represents a hydrogen atom or the like] or a salt thereof.